ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements with these filters
MPS Pharmaa Limited announced the availability of its FY 2025-26 Annual Report on its website. It also requested shareholders to update their KYC and PAN details.
The company submitted its 32nd Annual Report and AGM notice for FY 2025-26. The meeting is scheduled for September 29, 2026.
MPS Pharmaa Ltd announced the outcome of its board meeting, fixing the 32nd AGM date and recommending new director and auditor appointments for shareholder approval.
MPS Pharmaa Limited has scheduled a board meeting on September 02, 2026, to consider the notice for the company's upcoming Annual General Meeting.
Advik Laboratories Ltd reported a net loss of ₹0.2 Cr for Q1 FY27.
MPS Pharmaa Limited will hold a board meeting on August 13, 2026, to consider and approve the company's un-audited financial results for the quarter ending June 30, 2026.
Advik Laboratories Ltd filed its quarterly shareholding pattern as of June 30, 2026. The filing provides the distribution of shares among promoters and public shareholders.
MPS Pharmaa Limited filed its Annual Secretarial Compliance Report for the financial year ended March 2026. The report details governance compliance and historical listing fee defaults.
Advik Laboratories Ltd reported a net loss of ₹0.4 Cr for Q4 FY26.
Advik Laboratories reported FY2026 audited financial results alongside the reappointment of internal auditors. The company continues to navigate operational challenges with a qualified audit opinion.
MPS Pharmaa Limited scheduled a Board Meeting on May 28, 2026, to approve FY26 audited financial results. The trading window remains closed until May 30, 2026.
MPS Pharmaa Limited (formerly Advik Laboratories Limited) confirmed it does not fall under the 'Large Corporate' category as of March 31, 2026. This disclosure complies with SEBI's framework for fund raising via debt securities issuance. The company remains exempt from specific debt-sourcing requirements mandated for large corporate entities.
MPS Pharmaa Limited (formerly Advik Laboratories Limited) reported nil investor complaints for the quarter ended March 31, 2026. The company started, received, and disposed of zero complaints during the period, ending the quarter with no unresolved grievances.